Cognitive Impairment in Schizophrenia: a Review of Developmental and Genetic Models, and Pro-cognitive Profile of the Optimised D3 > D2 Antagonist, S33138
Thérapie, 63 3 (2008) 187-229
Publié en ligne : 2008-08-23
Article cité par
La fonctionnalité Article cité par… liste les citations d'un article. Ces citations proviennent de la base de données des articles de EDP Sciences, ainsi que des bases de données d'autres éditeurs participant au programme CrossRef Cited-by Linking Program. Vous pouvez définir une alerte courriel pour être prévenu de la parution d'un nouvel article citant " cet article (voir sur la page du résumé de l'article le menu à droite).
Article cité :
Citations de cet article :
60 203 (2022)
https://doi.org/10.1007/7854_2022_392
60 133 (2022)
https://doi.org/10.1007/7854_2022_326
Dual-acting agents for improving cognition and real-world function in Alzheimer’s disease: Focus on 5-HT6 and D3 receptors as hubs
Mark J. Millan, Anne Dekeyne, Alain Gobert, Mauricette Brocco, Clotilde Mannoury la Cour, Jean-Claude Ortuno, David Watson and Kevin C.F. FoneNeuropharmacology 177 108099 (2020)
https://doi.org/10.1016/j.neuropharm.2020.108099
Enhancing cognition through pharmacological and environmental interventions: Examples from preclinical models of neurodevelopmental disorders
Lorenzo Morè, Julie C. Lauterborn, Francesco Papaleo and Riccardo BrambillaNeuroscience & Biobehavioral Reviews 110 28 (2020)
https://doi.org/10.1016/j.neubiorev.2019.02.003
Animal Models for the Study of Human Disease
David Feifel and Paul D. ShillingAnimal Models for the Study of Human Disease 587 (2017)
https://doi.org/10.1016/B978-0-12-809468-6.00023-1
Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT6 receptor ligands with significant selectivity for D3 over D2 receptors
Oscar M. Saavedra, Delphine Karila, Dominique Brossard, et al.Bioorganic & Medicinal Chemistry 25 (1) 38 (2017)
https://doi.org/10.1016/j.bmc.2016.10.010
The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders
Mark J Millan, Jean-Michel Rivet and Alain GobertJournal of Psychopharmacology 30 (11) 1099 (2016)
https://doi.org/10.1177/0269881116672342
The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets
Manato Kotani, Takeshi Enomoto, Takeshi Murai, et al.Behavioural Brain Research 305 212 (2016)
https://doi.org/10.1016/j.bbr.2016.02.031
Targeting the dopamine D3 receptor: an overview of drug design strategies
Antoni Cortés, Estefanía Moreno, Mar Rodríguez-Ruiz, Enric I. Canela and Vicent CasadóExpert Opinion on Drug Discovery 11 (7) 641 (2016)
https://doi.org/10.1080/17460441.2016.1185413
The dopamine D 3 -preferring D 2 /D 3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia
David J.G. Watson, Madeleine V. King, Istvan Gyertyán, et al.European Neuropsychopharmacology 26 (2) 208 (2016)
https://doi.org/10.1016/j.euroneuro.2015.12.020
Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases
Samuele Maramai, Sandra Gemma, Simone Brogi, et al.Frontiers in Neuroscience 10 (2016)
https://doi.org/10.3389/fnins.2016.00451
Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation
Roberto Maggio, Marco Scarselli, Marta Capannolo and Mark J. MillanEuropean Neuropsychopharmacology 25 (9) 1470 (2015)
https://doi.org/10.1016/j.euroneuro.2014.09.016
13 1 (2014)
https://doi.org/10.1007/7355_2014_51
Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment
Mark J. Millan, Kevin Fone, Thomas Steckler and William P. HoranEuropean Neuropsychopharmacology 24 (5) 645 (2014)
https://doi.org/10.1016/j.euroneuro.2014.03.008
On ‘polypharmacy’ and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal
Mark J. MillanThe International Journal of Neuropsychopharmacology 17 (07) 1009 (2014)
https://doi.org/10.1017/S1461145712001496
Transient and rapid activation of Akt/GSK‐3β and mTORC1 signaling by D3 dopamine receptor stimulation in dorsal striatum and nucleus accumbens
Marie‐Josèphe Salles, Denis Hervé, Jean‐Michel Rivet, Sophie Longueville, Mark J. Millan, Jean–Antoine Girault and Clotilde Mannoury la CourJournal of Neurochemistry 125 (4) 532 (2013)
https://doi.org/10.1111/jnc.12206
Dopamine D3 receptor antagonism—still a therapeutic option for the treatment of schizophrenia
Gerhard Gross, Karsten Wicke and Karla U. DrescherNaunyn-Schmiedeberg's Archives of Pharmacology 386 (2) 155 (2013)
https://doi.org/10.1007/s00210-012-0806-3
The potential role of dopamine D3 receptor neurotransmission in cognition
Shinichiro Nakajima, Philip Gerretsen, Hiroyoshi Takeuchi, et al.European Neuropsychopharmacology 23 (8) 799 (2013)
https://doi.org/10.1016/j.euroneuro.2013.05.006
Mathematical modelling of [11C]-(+)-PHNO human competition studies
Graham E. Searle, John D. Beaver, Andri Tziortzi, et al.NeuroImage 68 119 (2013)
https://doi.org/10.1016/j.neuroimage.2012.11.033
In Vivo Occupancy of Dopamine D3 Receptors by Antagonists Produces Neurochemical and Behavioral Effects of Potential Relevance to Attention-Deficit–Hyperactivity Disorder
V. Barth, A.B. Need, E.T. Tzavara, B. Giros, C. Overshiner, S.D. Gleason, M. Wade, A.M. Johansson, K. Perry, G.G. Nomikos and J.M. WitkinThe Journal of Pharmacology and Experimental Therapeutics 344 (2) 501 (2013)
https://doi.org/10.1124/jpet.112.198895
Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: The CNTRICS initiative
Mark J. Millan and Karen L. BalesNeuroscience & Biobehavioral Reviews 37 (9) 2166 (2013)
https://doi.org/10.1016/j.neubiorev.2013.09.012
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy
Mark J. Millan, Yves Agid, Martin Brüne, et al.Nature Reviews Drug Discovery 11 (2) 141 (2012)
https://doi.org/10.1038/nrd3628
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
S Miyamoto, N Miyake, L F Jarskog, W W Fleischhacker and J A LiebermanMolecular Psychiatry 17 (12) 1206 (2012)
https://doi.org/10.1038/mp.2012.47
Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment
David J. G. Watson, Charles A. Marsden, Mark J. Millan and Kevin C. F. FoneThe International Journal of Neuropsychopharmacology 15 (04) 471 (2012)
https://doi.org/10.1017/S1461145711000435
Pharmacological or genetic blockade of the dopamine D3 receptor increases cell proliferation in the hippocampus of adult mice
Martin Egeland, Xiaoqun Zhang, Mark J. Millan, Elisabeth Mocaer and Per SvenningssonJournal of Neurochemistry 123 (5) 811 (2012)
https://doi.org/10.1111/jnc.12011
Novel Antischizophrenia Treatments
Gerhard Gross and Karla DrescherHandbook of Experimental Pharmacology, Novel Antischizophrenia Treatments 213 167 (2012)
https://doi.org/10.1007/978-3-642-25758-2_7
Selective Blockade of Dopamine D3 Receptors Enhances while D2 Receptor Antagonism Impairs Social Novelty Discrimination and Novel Object Recognition in Rats: A Key Role for the Prefrontal Cortex
David JG Watson, Florence Loiseau, Manuela Ingallinesi, et al.Neuropsychopharmacology 37 (3) 770 (2012)
https://doi.org/10.1038/npp.2011.254
Animal models of schizophrenia
CA Jones, DJG Watson and KCF FoneBritish Journal of Pharmacology 164 (4) 1162 (2011)
https://doi.org/10.1111/j.1476-5381.2011.01386.x
Influence of social isolation in the rat on serotonergic function and memory – Relevance to models of schizophrenia and the role of 5-HT6 receptors
Charles A. Marsden, Madeleine V. King and Kevin C.F. FoneNeuropharmacology 61 (3) 400 (2011)
https://doi.org/10.1016/j.neuropharm.2011.03.003
Are impairments of time perception in schizophrenia a neglected phenomenon?
Olivier Bonnot, Marie de Montalembert, Solenn Kermarrec, et al.Journal of Physiology-Paris 105 (4-6) 164 (2011)
https://doi.org/10.1016/j.jphysparis.2011.07.006
Imaging Dopamine D3 Receptors in the Human Brain with Positron Emission Tomography, [11C]PHNO, and a Selective D3 Receptor Antagonist
Graham Searle, John D. Beaver, Robert A. Comley, et al.Biological Psychiatry 68 (4) 392 (2010)
https://doi.org/10.1016/j.biopsych.2010.04.038
From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease
Mark J. MillanPharmacology & Therapeutics 128 (2) 229 (2010)
https://doi.org/10.1016/j.pharmthera.2010.06.002
Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders
Christian A. Heidbreder and Amy H. NewmanAnnals of the New York Academy of Sciences 1187 (1) 4 (2010)
https://doi.org/10.1111/j.1749-6632.2009.05149.x
The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures
Mark J. Millan, Jerry J. Buccafusco, Florence Loiseau, et al.The International Journal of Neuropsychopharmacology 13 (08) 1035 (2010)
https://doi.org/10.1017/S1461145710000775
Blockade of dopamine D3 receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: Similar actions of D1 receptor agonists, but not of D2 antagonists
Florence Loiseau and Mark J. MillanEuropean Neuropsychopharmacology 19 (1) 23 (2009)
https://doi.org/10.1016/j.euroneuro.2008.07.012
Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: Improvements of affinity and selectivity for D3 versus D2 receptors
Jean-Louis Peglion, Christophe Poitevin, Clotilde Mannoury La Cour, Delphine Dupuis and Mark J. MillanBioorganic & Medicinal Chemistry Letters 19 (8) 2133 (2009)
https://doi.org/10.1016/j.bmcl.2009.03.015
Dual- and Triple-Acting Agents for Treating Core and Co-morbid Symptoms of Major Depression: Novel Concepts, New Drugs
Mark J. MillanNeurotherapeutics 6 (1) 53 (2009)
https://doi.org/10.1016/j.nurt.2008.10.039
The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats
Xiao-Qing Peng, Charles R. Ashby, Krista Spiller, et al.Neuropharmacology 56 (4) 752 (2009)
https://doi.org/10.1016/j.neuropharm.2008.12.007